PSYD_0114: KCL

<i>This record is part of the Psy-ShareD database. The Psy-ShareD database will host pre-existing structural MRI data collected at different global sites that will be suitable for region of interest, voxel-based morphometry, cortical thickness and surface area analytical approaches. To access this database, complete the Data Access Request Form by following the link on this page under the Licence ‘Psy-ShareD Data Access Request’. For more information, follow the link listed in Related Materials.</i><b>Clinical High-Risk follow-up for PSYD_0102: KCL</b><b>Contributors and PI’s: </b>Matthew KemptonInstitute of Psychiatry, Psychology and Neuroscience (IOPPN),<b> </b>King’s College London, U.K.<b>Key Details &amp; Variables</b><b>Data Type</b>Feature Data<b>Age Range</b>18-35<b>Number of Participants</b>47<b>Diagnostic Criteria</b>CHR (follow up for PSYD_0102)<b>Number of Clinical Subjects</b>5<b>Number of Clinical Subjects (follow-up)</b>42<b>Number of Control Subjects</b>N/A<b>Number of Control Subjects (follow-up)</b>N/A<b>Demographic Information</b>Age, Sex, Education, Ethnicity, Handedness<b>Clinical Measures</b>PANSS, CAARMS, PSYRATS<b>Cognitive Measures</b>WRAT, NART, WAIS Digit Span, F-A-S Verbal Fluency/ Sematic Fluency<b>Clinical Functioning Measures</b>N/A<b>Antipsychotic Medication Information Recorded</b>Yes<b>Antipsychotic Medication Name/ Antipsychotic Type</b>Name<b>Antipsychotic Dose Recorded</b>Yes<b>CPZ Equivalents Recorded</b>No<b>Other Medication Variables Recorded</b>Yes<b>Recreational Drug/ Alcohol Use</b>Yes<i>Note: the above table features key details and variables and is not an exhaustive list.</i>

<i>本数据集隶属于Psy-ShareD数据库。Psy-ShareD数据库将收录全球各采集站点已有的结构性磁共振成像（structural MRI）数据，适用于感兴趣区域分析、基于体素的形态测量学、皮层厚度及皮层表面积等分析方法。如需使用该数据库，请点击本页面“Psy-ShareD数据使用申请”许可项下的链接，填写数据使用申请表。更多信息请参阅相关材料中列出的链接。</i><b>PSYD_0102项目临床高危人群随访研究：伦敦国王学院（KCL）</b><b>项目贡献者与首席研究员：</b>Matthew Kempton，英国伦敦国王学院精神病学、心理学与神经科学研究所（Institute of Psychiatry, Psychology and Neuroscience, IOPPN）<b>核心细节与变量</b><b>数据类型</b>特征数据<b>年龄范围</b>18-35岁<b>参与者总数</b>47名<b>诊断标准</b>临床高危（CHR，针对PSYD_0102项目的随访研究）<b>临床受试者数量</b>5名<b>临床受试者随访人数</b>42名<b>对照受试者数量</b>无（N/A）<b>对照受试者随访人数</b>无（N/A）<b>人口统计学信息</b>年龄、性别、受教育程度、种族、利手性<b>临床评估量表</b>阳性与阴性症状量表（Positive and Negative Syndrome Scale, PANSS）、临床高危精神状态综合评估量表（Comprehensive Assessment of At-Risk Mental States, CAARMS）、精神病性症状评定量表（Psychotic Symptoms Rating Scales, PSYRATS）<b>认知评估工具</b>广泛成就测验（Wide Range Achievement Test, WRAT）、成人阅读测验（National Adult Reading Test, NART）、韦氏成人智力量表数字广度测验（WAIS Digit Span）、F-A_S言语流畅性/语义流畅性测验<b>临床功能评估量表</b>无（N/A）<b>抗精神病药物信息记录情况</b>是<b>抗精神病药物名称/药物类型</b>已记录药物名称<b>抗精神病药物剂量记录情况</b>是<b>氯丙嗪等效剂量（CPZ Equivalents）记录情况</b>否<b>其他药物相关变量记录情况</b>是<b>娱乐性药物/酒精使用情况</b>是<i>注：上述内容仅列出核心细节与变量，并非完整清单。</i>